With the many hundreds of assay platforms potentially available, scouting out the right one for your drug is just as important as the mission of matching your drug to the right patient pool. This May in Boston, we'll address the technical and business capabilities that pharma companies must look for in prospective Dx partners and more at the 2nd Annual Future of Companion Diagnostics Commercialization Summit. For more information on this event, download the brochure. If you'd like to join us in Boston, as a reader of this blog when you register to join us and mention code XP1812BLOG to save 15% off the standard rate.Featured Session: Commercial Considerations that Must Factor into your Companion Diagnostic Partnership Decisions
Featured Speaker: Andrea Lauber, Head, Transactions for Clinical Biomarkers Pharmacodiagnostics, BRISTOL-MYERS SQUIBB
About the session: There is no one-size-fits-all plan for the development of companion diagnostics, as the sheer diversity of platforms involved for each drug is beyond the scope of any single company. Scouting out the right partner is as critically important as matching drugs to the right patients.
- • Grasp the differences in sunk costs required for each partner
- • Grow trust and cooperation that can lead to multiple projects
- • Allow the greatest lead time for careful assessment of prospective partners
|
Share this article with your social network, just click below to share now!
|
|
|
No comments :
Post a Comment